Home » Stocks » FDMT

4D Molecular Therapeutics, Inc. (FDMT)

Stock Price: $34.87 USD 1.62 (4.87%)
Updated Apr 22, 2021 4:00 PM EDT - Market closed
Market Cap 224.23M
Revenue (ttm) 13.61M
Net Income (ttm) -56.69M
Shares Out 6.43M
EPS (ttm) -8.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 22
Last Price $34.87
Previous Close $33.25
Change ($) 1.62
Change (%) 4.87%
Day's Open 33.56
Day's Range 33.10 - 36.28
Day's Volume 100,831
52-Week Range 30.55 - 55.11

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

- First patient dosed in the 4D-310 Phase 1/2 clinical trial in Fabry disease

4 weeks ago - GlobeNewsWire

EMERYVILLE, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: 4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therap...

1 month ago - GlobeNewsWire

Andreas Halvorsen (Trades, Portfolio) has revealed two new buys in 4D Molecular Therapeutics Inc. (NASDAQ:FDMT) and AbCellera Biologics Inc. (NASDAQ:ABCL), according to GuruFocus' Real-Time Picks, a Pre...

Other stocks mentioned: ABCL
4 months ago - GuruFocus

EMERYVILLE, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT), a clinical-stage gene therapy company harnessing the power...

4 months ago - GlobeNewswire

EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT), a clinical-stage gene therapy company harnessing the power...

4 months ago - GlobeNewswire

4D Molecular Therapeutics, a Phase 1/2 gene therapy biotech developing novel AAVs for ophthalmic diseases, raised the proposed deal size for its upcoming IPO on Thursday. The Emeryville, CA-based compan...

4 months ago - NASDAQ

4D Molecular Therapeutics, which is developing targeted gene therapies for multiple diseases, filed on Tuesday with the SEC to raise up to $75 million in an initial public offering.

5 months ago - NASDAQ

4D Molecular Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

5 months ago - SEC

About FDMT

4D Molecular Therapeutics is a clinical-stage gene therapy company pioneering the development of product candidates using our targeted and evolved AAV vectors. We seek to unlock the full potential of gene therapy using our platform, Therapeutic Vector Evolution, which combines the power of directed evolution with our approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. Our targeted and evolved vectors are invented with the goal of being delivered through clinically routine, we... [Read more...]

Industry
Biotechnology
IPO Date
Dec 11, 2020
CEO
David Kirn
Employees
83
Stock Exchange
NASDAQ
Ticker Symbol
FDMT
Full Company Profile

Financial Performance

In 2020, FDMT's revenue was $13.61 million, an increase of 94.85% compared to the previous year's $6.99 million. Losses were -$56.69 million, 15.0% more than in 2019.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for FDMT is 56.00, which is an increase of 60.60% from the latest price.

Price Target
$56.00
(60.60% upside)